Literature DB >> 15497097

Molecular mechanisms in thrombotic thrombocytopenic purpura.

Han-Mou Tsai1.   

Abstract

Thrombotic thrombocytopenic purpura (TTP) is characterized by thrombocytopenia and microangiopathic hemolysis. Unlike the typical hemolytic uremic syndrome (HUS), which follows infection with shiga toxin-producing microorganisms, most cases of TTP do not have an obvious etiology. Recent studies revealed that a plasma zinc metalloprotease ADAMTS (a disintegrin and metalloprotease with thrombospondin type 1 motif) 13 cleaves von Willebrand factor in a shear-dependent manner. Deficiency of ADAMTS13, due to autoimmune inhibitors of the protease or genetic mutation in the ADAMTS13 gene, results in a propensity to the development of von Willebrand factor-platelet aggregation and intravascular thrombosis characteristic of TTP. The identification of the molecular defect in TTP raises the prospect that this hitherto mysterious disorder will be managed with a more rationally designed strategy in the near future.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15497097     DOI: 10.1055/s-2004-835675

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  7 in total

Review 1.  Advantages and limits of ADAMTS13 testing in thrombotic thrombocytopenic purpura.

Authors:  Massimo Franchini; Pier Mannuccio Mannucci
Journal:  Blood Transfus       Date:  2008-07       Impact factor: 3.443

2.  Enzymatically active ADAMTS13 variants are not inhibited by anti-ADAMTS13 autoantibodies: a novel therapeutic strategy?

Authors:  Wenhua Zhou; Lingli Dong; David Ginsburg; Eric E Bouhassira; Han-Mou Tsai
Journal:  J Biol Chem       Date:  2005-10-03       Impact factor: 5.157

Review 3.  Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assays.

Authors:  Suresh G Shelat; Jihui Ai; X Long Zheng
Journal:  Semin Thromb Hemost       Date:  2005-12       Impact factor: 4.180

Review 4.  Postoperative thrombotic thrombocytopenic purpura.

Authors:  Ahmet Emre Eskazan; Deram Buyuktas; Teoman Soysal
Journal:  Surg Today       Date:  2013-12-29       Impact factor: 2.549

5.  Complement Inhibition in the Treatment of SLE-Associated Thrombotic Thrombocytopenic Purpura.

Authors:  Alexis Boneparth; L Nandini Moorthy; Lynne Weiss; Hariprem Rajasekhar; Susan Murphy; Richard A Drachtman
Journal:  Glob Pediatr Health       Date:  2015-01-30

6.  Prediction of spacer-α6 complex: a novel insight into binding of ADAMTS13 with A2 domain of von Willebrand factor under forces.

Authors:  Xiang Fang; Jiangguo Lin; Ying Fang; Jianhua Wu
Journal:  Sci Rep       Date:  2018-04-10       Impact factor: 4.379

Review 7.  The thrombotic microangiopathies.

Authors:  Lawrence Copelovitch; Bernard S Kaplan
Journal:  Pediatr Nephrol       Date:  2007-09-30       Impact factor: 3.714

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.